CFDB - Cystic Fibrosis DataBase

  1. Home
  2. Database
Search (?)
at least one term
all terms
Advanced search
primary studies published RCT

Inhaled mannitol improves lung function in cystic fibrosis.

  • Year: 2008
  • Date: 2008
  • Author: Jaques A
Source

Chest. 2008 Jun;133(6):1388-96. Epub 2008 Mar 13.

Study design (if review, criteria of inclusion for studies)

randomized, double-blind, placebo-controlled, crossover study.

Participants

Thirty-nine subjects with mild-to-moderate CF lung disease

Interventions

Patients inhaled 420 mg of mannitol or placebo twice daily for 2 weeks. Following a 2-week washout period, subjects were entered in the reciprocal treatment arm.

Outcome measures

Lung function, respiratory symptoms, quality of life, and safety were assessed.

Main results

Mannitol treatment increased FEV(1) from baseline by a mean of 7.0% (95% confidence interval [CI], 3.3 to 10.7) compared to placebo 0.3% (95% CI, - 3.4 to 4.0; p < 0.001). The absolute improvement with mannitol therapy was 121 mL (95% CI, 56.3 to 185.7), which was significantly more than that with placebo (0 mL; 95% CI, - 64.7 to 64.7). The forced expiratory flow in the middle half of the FVC increased by 15.5% (95% CI, - 6.5 to 24.6) compared to that with placebo (increase, 0.7%; 95% CI, - 8.3 to 9.7; p < 0.02). The safety profile of mannitol was adequate, and no serious adverse events related to treatment were observed

Authors' conclusions

Inhaled mannitol treatment over a period of 2 weeks significantly improved lung function in patients with CF. Mannitol therapy was safe and well tolerated.

Keywords: Adolescent; Adult; Child; Inhalation OR nebulised; Mannitol; pharmacological_intervention; Airway clearance drugs -expectorants- mucolytic- mucociliary-; Respiratory System Agents;